Smoking cessation drugs may not increase depression risk: Study

New York, April 23 (IANS) Contrary to popular perception, smoking cessation drugs do not increase the risk of serious neuropsychiatric adverse effects such as depression, hostility or suicidal behaviour, says a large study.

Researchers have found that compared to the nicotine patch and a placebo the smoking cessation drugs varenicline and bupropion do not show a significant increase in neuropsychiatric adverse events.

“There are one billion smokers in the world and nearly six million smoking-related deaths each year, but there are only three approved medication treatments for quitting: nicotine replacement therapies like the patch and the two non-nicotine medications, bupropion and varenicline,” said first author of the study Robert Anthenelli, professor at the University of California San Diego School of Medicine.

The study, published online in the journal The Lancet, is important because it prospectively examined the neuropsychiatric safety risks and quit-enhancing potential of the three medication classes versus placebo in a rigorous, adequately-sized, randomised controlled trial, Anthenelli said.

The researchers sought to directly assess the safety and efficacy of varenicline and bupropion compared to the nicotine patch and to a placebo in smokers with and without psychiatric disorders.

The study involved examination of more than 8,000 smokers seeking to quit in 16 countries over a period from November 2011 to January 2015.

Trial participants, investigators and research personnel were blinded to who received which treatment.

In terms of safety, approximately two percent of non-psychiatric participants reported moderate or severe adverse neuropsychiatric events for any of the treatments.

In the cohort of participants with psychiatric disorders, moderate and severe adverse neuropsychiatric events were slightly higher across the board: 6.5 percent for varenicline, 6.7 percent for bupropion, 5.3 percent for the nicotine patch and 4.9 percent for placebo.

Anthenelli said the risk difference in the incidence of serious neuropsychiatric adverse events for varenicline and bupropion was not significantly higher than placebo – but that psychiatric patients trying to stop smoking are likely to have more confounding factors in treatment and appear to have a harder time quitting.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here